- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$8.57 BnMarket Estimate, 2026
$10.50 BnMarket Forecast, 2034
$53.45 BnCAGR, 2026–2034
22.56%Executive Summary: Global Companion Diagnostics Market
- Market Scope: Comprehensive global companion diagnostics market analysis covering indications, technology platforms, regional performance, key players, and adoption metrics.
- Market Valuation: Valued at USD 8.57 billion (2025), estimated at USD 10.50 billion (2026), and projected to reach USD 53.45 billion by 2034, registering an extraordinary CAGR of 22.56% (2026–2034).
- Primary Growth Drivers: Proliferation of targeted therapies, shifting trends toward personalized/precision medicine, rising cancer and chronic disease incidence, and increased focus on next-generation sequencing and molecular diagnostics. Key market restraints include a lack of skilled professionals, high equipment installation and maintenance costs, and software updating challenges.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment (2025/Historical Position) | Fastest-Growing Segment |
|---|---|---|
| By Indications | Oncology (dominated with the most significant market share driven by cancer biomarker detection) | Lung Cancer (fastest-growing subset within the oncology indication segment) |
| By Technology | Molecular Diagnostics / Real-Time PCR (holds the highest share during the forecast period) | Gene Sequencing (showcasing steady, robust expansion due to multi-gene analysis capabilities) |
| By Region | North America (accounted for the leading regional share backed by advanced technology adoption) | Asia Pacific (deemed to hit the highest growth rate and CAGR in foreseen years) |
| Notable Country Growth | United States & Major European Nations (UK, Germany, France) | Latin America (projected at a CAGR of 22.83%) & India (promising CAGR in APAC) |
Major Market Players & Market Structure
Market Structure: Highly competitive global diagnostics and biotechnology landscape featuring key players competing through FDA-cleared assay launches, pharma-diagnostic co-developments, and technological innovations.
Key Companies: Abbott Molecular Inc., Roche Molecular Systems Inc. (Ventana Medical Systems), Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc., Biogenex Laboratories Inc., and Thermo Fisher Scientific Inc.
Global Companion Diagnostics Market Size
The global companion diagnostics market size was valued at USD 8.57 billion in 2025. The global market size is forecasted to grow to USD 53.45 billion by 2034 from USD 10.50 billion in 2026, showcasing a CAGR of 22.56% from 2026 to 2034.
MARKET DRIVERS
The increasing number of targeted therapies, the shifting trend towards personalized medicine, and the rise in the prevalence of improving treatment procedures by properly analyzing diagnosis results are majorly accelerating the growth of the global companion diagnostics market.
In addition, an increase in the focus on next-generation sequencing technology and diagnostics procedures has an immense role in developing drugs, potentially influencing the growth of the global companion diagnostics market. Furthermore, an increasing number of diagnostic centers with the latest equipment with private and public organizations' help and growing spending on healthcare also fuel the market's growth rate. In addition, companion diagnostics promotes better treatment options suitable for the patient for a particular disease, boosting the global companion diagnostics market.
MARKET RESTRAINTS
However, a lack of awareness and skilled professionals and the cost of installing and maintaining the equipment require vast amounts that small-scale companies cannot afford, slowly impeding market growth. Furthermore, frequent changes in the software and the time taken to update the existing one are a little more. This attribute is limiting the demand of the market. In addition, the shortage of skilled technicians to resolve the complications in real-time applications has remained challenging for the market.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2026 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Indications, Technology, and Region |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Challenges, Restraints, Opportunities; PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Market Leaders Profiled | Abbott Molecular Inc., Roche Molecular Systems Inc., Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc. |
SEGMENTAL ANALYSIS
By Indications Insights
Oncology is the highest revenue-creating segment based on indications, as most of the companion diagnostics have been developed to detect one or the other cancer biomarkers. Oncology held the most significant market share in 2023 and is likely to continue the same trend during the forecast period. Due to the growing occurrence of cancer worldwide, increasing part of companion diagnostics in raising awareness about the humanizing medicine treatment of cancer helps the oncology segment grow. Growing benefits of biomarkers for cancer diagnosis and advanced technology in cancer diagnostics and treatment.
Within oncology, lung cancer is the most common cancer found in people worldwide and is likely to grow faster in the forthcoming years.
By Technology Insights
Based on technology, the molecular diagnostics segment holds the highest share during the forecast period. With this technology, the Real-Time PCR segment is likely to continue its growth during the period. This PCR is used to identify the causes of many diseases, which drives this segment's growth.
The gene Sequencing segment is expected to showcase decent CAGR during the forecast period due to the potentiality of sequencing thousands of genes.
REGIONAL ANALYSIS
Regionally, North America accounted for the leading share in the global companion diagnostics market in 2023, with revenue rising in developed and developing countries. In addition, the adoption of advanced technologies and the launch of various equipment favoring the end-user are further gearing up the market growth in North America. As a result, the U.S. companion diagnostics market is predicted to grow at a significant CAGR during the forecast period, and Canada is expected to showcase a healthy CAGR.
The European market accounted for a substantial share of the global market in 2023. The rise in the number of patients with diseases like cancer, cardiovascular, and others fuels the market's growth. Also, increasing knowledge over launching companion diagnostics procedures for various applications prompts the market's demand. As a result, EU Countries such UK, Germany, and France are estimated to register the most significant share of the European market during the forecast period.
Asia Pacific has witnessed a tremendous growth rate in the past decade and is also deemed to hit the highest CAGR in foreseen years. The growing use of biomarkers for various purposes in the medical sector is lavishing the market's growth rate. India is predicted to register a promising CAGR in the APAC region during the forecast period. Other countries such as China, Japan, and Australia are estimated to grow healthy from 2024 to 2032.
The Latin American region is projected to grow at a CAGR of 22.83% during the forecast period.
The Middle East and Africa are to have a positive growth rate shortly with the rising support from the government by introducing reimbursement schemes to allow quality treatment for ordinary people.
KEY MARKET PLAYERS
Companies playing a vital role in the global companion diagnostics market profiled in this report are
- Abbott Molecular Inc.
- Roche Molecular Systems Inc.
- Leica Biosystems Nussloch GmbH
- bioMérieux Inc.
- Dako Inc.
- Qiagen Ltd.
- ARUP Laboratories
- Myriad Genetics Inc.
- Biogenex Laboratories Inc.
- Ventana Medical Systems Inc.
- Thermo Fisher Scientific Inc.
RECENT MARKET HAPPENINGS
In May 2020, Myriad received FDA clearance for MyChoice CDx as a companion diagnostic for Lynparza. It is for women who have ovarian cancer. The acceptance of mychoice helps clinicians identify women with ovarian cancer whose HRD is positive and who responds to the therapy.
- In April 2019, Qiagen launched the novel therascreen FGFR RGQ RT-PCR kit that works as a companion diagnostic. It is the first FDA-approved to treat Mestastatc Urothelial Cancer.
- In June 2015, the Ventana medical system (a part of Roche Group) received FDA clearance for VENTANA ALK (D5F3). It is a companion diagnostic that helps identify lung cancer patients for Pfizer's FDA-approved targeted therapy, XALKORI.
MARKET SEGMENTATION
This research report on the global companion diagnostics market has been segmented and sub-segmented based on indications, technology, and region.
By Indications
- Oncology
- Colorectal Cancer
- Lung Cancer
- Breast Cancer
- Gastric Cancer
- Melanoma
- Inflammation and Autoimmune Diseases
- Cardiovascular Diseases
- Central Nervous System Disorders
- Virology Diseases
By Technology
- Immunohistochemistry
- Molecular Diagnostics
- In-Situ Hybridization
- Real-Time PCR
- Gene Sequencing
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East and Africa